We are live on
!
Find out more
Entrada Therapeutics
TRDA
TRDA
47 hedge funds and large institutions have $334M invested in Entrada Therapeutics in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
467% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 3
167% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 6
42% more funds holding
Funds holding: 33 → 47 (+14)
0.53% more ownership
Funds ownership: 78.15% → 78.69% (+0.53%)
14% less capital invested
Capital invested by funds: $386M → $334M (-$52.2M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Holders
47
Holders Change
+14
Holders Change %
+42.42%
% of All Funds
0.76%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.05%
New
17
Increased
16
Reduced
6
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.96M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$878K |
| 3 |
Citigroup
New York
|
+$867K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$742K |
| 5 |
BlackRock
New York
|
+$708K |
Top Sellers
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$1.76M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$1.5M |
| 3 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
-$1.19M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$1M |
| 5 |
Goldman Sachs
New York
|
-$841K |
